Source: CureToday articles
The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with multiple myeloma who are ineligible for autologous stem cell transplant.
Recent Content
- FDA approves isatuximab-irfc combination for certain adults with multiple myeloma
- FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible Multiple Myeloma
- Characterization of MYC Rearrangements in Multiple Myeloma: an Optical Genome Mapping Approach
- Risk assessment and clinical implications of COVID-19 in multiple myeloma patients: A systematic review and meta-analysis
- Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis
- Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era
- Meta-analysis of effectiveness and safety of proteasome inhibitor-dependent maintenance treatment for multiple myeloma a systematic review
- Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients
- The acceptability of using wearable electronic devices to monitor physical activity of patients with Multiple Myeloma undergoing treatment: a systematic review
- Role of Autologous Transplant in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Triplets: A Systematic Review and Meta-Analysis